M&A

J&J chief Gorksy bullish on tax reform, plans $16B in repatriated overseas cash
Mass Device
Wed, 01/10/18 - 11:38 am
tax reform
JNJ
Pharma CEOs
Alex Gorsky
M&A
5 Things Amgen's CEO Just Said That Investors Need to Know
Motley Fool
Wed, 01/10/18 - 10:13 am
Amgen
Pharma CEOs
Bob Bradway
Prolia
M&A
5 Ways Gilead Sciences Plans to Return to Growth
Motley Fool
Tue, 01/9/18 - 10:55 pm
Gilead Sciences
HIV
liver disease
cell therapy
inflammation
M&A
Novo Nordisk puts $3B on the table for Ablynx
Biopharma Dive
Mon, 01/8/18 - 11:48 am
Novo Nordisk
Ablynx
M&A
Celgene aims to quell growth worries with $7B Impact deal
Biopharma Dive
Mon, 01/8/18 - 11:27 am
Celgene
Impact Biomedicines
M&A
CVS Health to acquire Apothecary By Design
GoinPharma
Sun, 01/7/18 - 12:38 pm
CVS Health
M&A
Apothecary by Design
After resisting a push to the auction block, Acorda preps for a sale and shares shoot up — report
Endpoints
Fri, 01/5/18 - 05:28 pm
Acorda
M&A
A Biotech VC's Outlook For 2018
Forbes
Fri, 01/5/18 - 05:27 pm
biotech
venture capital
venture
M&A
IPOs
To catch Apple, Fitbit invests in a company that makes a small patch to track blood sugar for diabetics
CNBC
Fri, 01/5/18 - 05:24 pm
Apple
Fitbit
wearables
devices
blood glucose monitoring
diabetes
M&A
Sanos
Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval
Endpoints
Fri, 01/5/18 - 10:05 am
Takeda
TiGenix
M&A
Crohn’s disease
gene therapy
Cx601
18 Reasons I Like Biotech Stocks in 2018
Motley Fool
Thu, 01/4/18 - 09:40 pm
biotech stocks
M&A
drug pricing
FDA
tax reform
Top 10 stories that had pharma execs talking
Biopharma Dive
Thu, 01/4/18 - 12:02 pm
M&A
Bristol-Myers Squibb
Opdivo
Express Scripts
Novartis
C-ART
Kymriah
Massachusetts
AbbVie
Kenneth Frazier
biosimilars
CVS Health Pfizer
Biotech sector ensures highest premium among M&A transactions
GoinPharma
Tue, 01/2/18 - 11:05 am
biotech
M&A
Kite Pharma
Gilead Sciences
JNJ
Actelion
Valeant strikes deal to reduce its portion of Allergan settlement to $96.25M
Canadian Business
Mon, 01/1/18 - 03:06 pm
Valeant Pharmaceuticals
Allergan
M&A
3 Bold Biotech Predictions For 2018!
Seeking Alpha
Thu, 12/28/17 - 11:30 am
biotech
M&A
FDA
drug approvals
Anthem Signals Intent To Compete With Optum In Buying Providers
Forbes
Thu, 12/28/17 - 09:26 am
Anthem
OptumRx
M&A
Medicare
Florida
Mallinckrodt builds pipeline through $1.2B Sucampo deal
Biopharma Dive
Thu, 12/28/17 - 09:20 am
Mallinckrodt
Sucampo
M&A
Biopharma trends to watch in 2018
BioPharma Dive
Sat, 12/23/17 - 11:45 pm
drug pricing
M&A
gene therapy
biosimilars
opioids
ophthalmology
3 Biotech Stocks That Soared This Week: Are They Buys?
Motley Fool
Sat, 12/23/17 - 11:39 pm
biotech
Ignyta
Roche
M&A
Molecular Templates
Biohaven Pharmaceuticals
trigriluzole
Roche Bets $1.7B More on Precision Oncology With Ignyta Deal
Xconomy
Fri, 12/22/17 - 09:51 am
Roche
Ignyta
M&A
precision medicine
oncology

Pages